Extemporaneous combination of donepezil and memantine to treat dementia in Alzheimer disease: evidence from Italian real-world data

References

• James G, Collin E, Lawrance M, et al. Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe. Soc Psychiatry Psychiatr Epidemiol. 2021;56(3):409–416.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Disease. Statistics from Epicentro – Epidemiology for public health. Istituto Superiore di Sanità. Available from https://www.epicentro.iss.it/en/alzheimer/.
   Google Scholar
• Italian National Statistics Institute – ISTAT. Italian resident population stratified by age class. Available from http://dati.istat.it/Index.aspx?DataSetCode=DCIS_POPRES1.
   Google Scholar
• Italian Medicines Agency. Nota 85. Available from https://www.aifa.gov.it/nota-85.
   Google Scholar
• Kaushik V, Smith ST, Mikobi E, et al. Acetylcholinesterase inhibitors: beneficial effects on comorbidities in patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2018;33(2):73–85.
   PubMed Web of Science ®Google Scholar
• Molino I, Colucci L, Fasanaro AM, et al. Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer’s disease: a review of clinical trials. ScientificWorldJournal. 2013;2013:925702.
   PubMed Web of Science ®Google Scholar
• Conway ME. Alzheimer’s disease: targeting the glutamatergic system. Biogerontology. 2020;21(3):257–274.
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stöffler A, et al. Memantine study group. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–1341.
   PubMed Web of Science ®Google Scholar
• Parsons CG, Danysz W, Dekundy A, et al. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res. 2013;24(3):358–369.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Refusal of the marketing authorisation for Acrescent (memantine hydrochloride/donepezil hydrochloride). EMA/CHMP/816079/2012. Available from www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-acrescent_en.pdf.
   Google Scholar
• European Medicine Agency. Refusal of the marketing authorisation for Balaxur (memantine hydrochloride/donepezil hydrochloride). EMA/CHMP/816057/2012. Available from www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-balaxur_en.pdf.
   Google Scholar
• Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe alzheimer’s disease. Drug Des Devel Ther. 2016;10:3267–3279.
   PubMed Web of Science ®Google Scholar
• Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol. 2015;22(6):889–898.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Exellence (NICE) Guidelines. Dementia: assessment, management and support for people living with dementia and their carers. Available from www.nice.org.uk/guidance/ng97/resources/dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109.
   Google Scholar
• Cartabellotta A, Eleopra R, Quintana S. Linee guida per la diagnosi, il trattamento e il supporto dei pazienti affetti da demenza. Evidence. 2018;1:e1000190.
   Google Scholar
• Caltagirone C, Bianchetti A, Di Luca M, et al. Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics. Drugs Aging. 2005;22(Suppl 1):1–26.
   PubMed Web of Science ®Google Scholar
• Agenzia Espanola de medicamentos y productos sanitarios. Ficha tecnica donepezilo/memantina tecnigen 10 mg/10 mg comprimidos recubiertos con pelicula. Available from https://cima.aemps.es/cima/pdfs/ft/85693/FT_85693.pdf.
   Google Scholar
• Gareri P, Putignano D, Castagna A, et al. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd patients affected with Alzheimer’s disease: the MEMAGE study. JAD. 2014;41(2):633–640.
   Web of Science ®Google Scholar
• Tifratene K, Duff FL, Pradier C, et al. Use of drug treatments for Alzheimer’s disease in France: a study on a national level based on the national Alzheimer’s data bank (Banque Nationale Alzheimer). Pharmacoepidemiol Drug Saf. 2012;21(9):1005–1012.
   PubMed Web of Science ®Google Scholar
• Brewer L, Bennett K, McGreevy C, et al. A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol. 2013;69(7):1467–1475.
   PubMed Web of Science ®Google Scholar
• Taipale H, Tanskanen A, Koponen M, et al. Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study. Int Clin Psychopharmacol. 2014;29(4):216–223.
   PubMed Web of Science ®Google Scholar
• Kuronen M, Koponen H, Nykänen I, et al. Use of anti-dementia drugs in home care and residential care and associations with neuropsychiatric symptoms: a cross-sectional study. BMC Geriatr. 2015;15:100.
   PubMed Web of Science ®Google Scholar
• Wübbeler M, Wucherer D, Hertel J, et al. Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use. BMC Health Serv Res. 2015 May 22;15(1):205.
   PubMed Web of Science ®Google Scholar
• Donegan K, Fox N, Black N, et al. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. Lancet Public Health. 2017;2(3):e149–e156.
   PubMed Web of Science ®Google Scholar
• Calvó-Perxas L, Turró-Garriga O, Vilalta-Franch J, et al. Trends in the prescription and Long-Term utilization of antidementia drugs among patients with Alzheimer’s disease in Spain: a cohort study using the registry of dementias of girona. Drugs Aging. 2017;34(4):303–310.
   PubMed Web of Science ®Google Scholar
• Bruno G, Mancini M, Bruti G, et al. Costs and resource use associated with Alzheimer’s disease in Italy: results from an observational study. J Prev Alzheimers Dis. 2018;5(1):55–64.
   PubMed Web of Science ®Google Scholar
• Castagna A, Fabbo A, Manzo C, et al. A retrospective study on the benefits of combined citicoline, memantine, and acetylcholinesterase inhibitor treatments in older patients affected with Alzheimer’s disease. JAD. 2021;79(4):1509–1515.
   Web of Science ®Google Scholar
• Scuteri D, Vulnera M, Piro B, et al. Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a Centre for cognitive disturbances and dementia. Eur J Clin Pharmacol. 2021;77(2):241–249.
   PubMed Web of Science ®Google Scholar
• Gareri P, Cotroneo AM, Orsitto  , et al. The CITIDEMAGE study: stressing the cholinergic hypothesis for the best outcomes in dementia patients: human/human trials: cognitive enhancement. Alzheimers Dement. 2020;16:e038178.
   Google Scholar
• Italian Medicines Agency. Modifica nota 85. Gazzetta Ufficiale. AIFA. [cited 2009 Mar 19]. Available from www.gazzettaufficiale.it/do/atto/serie_generale/caricaPdf?cdimg=09A0268300100010110001&dgu=2009-03-19&art.dataPubblicazioneGazzetta=2009-03-19&art.codiceRedazionale=09A02683&art.num=1&art.tiposerie=SG.
   Google Scholar
• Richter H, Dombrowski S, Hamer H, et al. Use of a German longitudinal prescription database (LRx) in pharmacoepidemiology. Ger Med Sci. 2015;13:Doc14.
   PubMedGoogle Scholar
• Helwig U, Kostev K, Schmidt C. Comparative analysis of 3-year persistence with vedolizumab compared with antibodies against tumor necrosis factor-alpha in patients with inflammatory bowel disease in Germany: retrospective analysis of a large prescription database. J Clin Gastroenterol. 2021;55(1):e1–e7.
   PubMed Web of Science ®Google Scholar
• Richette P, Allez M, Descamps V, et al. Impact de la COVID-19 sur les initiations et les renouvellements des biothérapies et traitements synthétiques ciblés en France. Rev Rhum Ed Fr. 2020;87:a14.
   Google Scholar
• Joumaa H, Sigogne R, Maravic M, et al. Artificial intelligence to differentiate asthma from COPD in medico-administrative databases. BMC Pulm Med. 2022;22(1):357.
   PubMed Web of Science ®Google Scholar
• Vilcu AM, Blanchon T, Sabatte L, et al. Cross-validation of an algorithm detecting acute gastroenteritis episodes from prescribed drug dispensing data in France: comparison with clinical data reported in a primary care surveillance system, winter seasons 2014/15 to 2016/17. BMC Med Res Methodol. 2019 May 31;19(1):110.
   PubMed Web of Science ®Google Scholar
• Putignano D, Bruzzese D, Orlando V, et al. Differences in drug use between men and women: an italian cross sectional study. BMC Womens Health. 2017;17(1):73.
   PubMed Web of Science ®Google Scholar
• Federici MO, McQuillan J, Biricolti G, et al. Utilization patterns of Glucagon-Like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Italy: a retrospective cohort study. Diabetes Ther. 2018;9(2):789–801.
   PubMed Web of Science ®Google Scholar
• Research Institute of SIMG. XIV report Health Search. 2021. Available from https://report.healthsearch.it/2021/Report_XIV.pdf.
   Google Scholar
• Ravera M, Cannavò R, Noberasco G, et al. High performance of a risk calculator that includes renal function in predicting mortality of hypertensive patients in clinical application. J Hypertens. 2014;32(6):1245–1254.
   PubMed Web of Science ®Google Scholar
• Katz P, Pegoraro V, Liedgens H. Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe – the role of the lidocaine 5% medicated plaster. Curr Med Res Opin. 2017;33(8):1481–1489.
   PubMed Web of Science ®Google Scholar
• Di Marco F, Santus P, Terraneo S, et al. Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study. NPJ Prim Care Respir Med. 2017;27(1):51.
   PubMed Web of Science ®Google Scholar
• Agostoni E, Barbanti P, Frediani F, et al. Real-world insights on the management of migraine patients: an Italian nationwide study. Curr Med Res Opin. 2019;35(9):1545–1554.
   PubMed Web of Science ®Google Scholar
• Colombo GL, Heiman F, Peduto I. Utilization of healthcare resources in osteoarthritis: a cost of illness analysis based on real-world data in Italy. Ther Clin Risk Manag. 2021;17:345–356.
   PubMed Web of Science ®Google Scholar
• Pegoraro V, Heiman F, Levante A, et al. An Italian individual-level data study investigating on the association between air pollution exposure and covid-19 severity in primary-care setting. BMC Public Health. 2021 May 12;21(1):902.
   PubMed Web of Science ®Google Scholar
• Volpe M, Pegoraro V, Peduto I, et al. Extemporaneous combination therapy with nebivolol/zofenopril in hypertensive patients: usage in Italy. Curr Med Res Opin. 2022;38(10):1673–1681.
   PubMed Web of Science ®Google Scholar
• Levi M, Pasqua A, Cricelli I, et al. Patient adherence to olmesartan/amlodipine combinations: fixed versus extemporaneous combinations. J Manag Care Spec Pharm. 2016;22(3):255–262.
   PubMedGoogle Scholar
• Prieto-Merino D, Mulick A, Armstrong C, et al. Estimating proportion of days covered (PDC) using real-world online medicine suppliers’ datasets. J Pharm Policy Pract. 2021;14(1):113.
   PubMed Web of Science ®Google Scholar
• Asamoah-Boaheng M, Osei Bonsu K, Farrell J, et al. Measuring medication adherence in a population-based asthma administrative pharmacy database: a systematic review and Meta-Analysis. CLEP. 2021;13:981–1010.
   Web of Science ®Google Scholar
• Italian Medicines Agency. Ebixa. Riassunto delle caratteristiche del prodotto. Available from https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000911_035681_RCP.pdf&sys=m0b1l3.
   Google Scholar
• Italian Medicines Agency. Donepezil Teva. Riassunto delle caratteristiche del prodotto. Available from https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000813_041733_RCP.pdf&sys=m0b1l3.
   Google Scholar
• Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177–186.
   PubMed Web of Science ®Google Scholar
• Nishimura S, Kumamaru H, Shoji S, et al. Adherence to antihypertensive medication and its predictors among non-elderly adults in Japan. Hypertens Res. 2020;43(7):705–714.
   PubMed Web of Science ®Google Scholar
• Khan R, Kaul P, Islam S, et al. Drug adherence and long-term outcomes in non-revascularized patients following acute myocardial infarction. Am J Cardiol. 2021;152:49–56.
   PubMed Web of Science ®Google Scholar
• Gualano MR, Corradi A, Voglino G, et al. Beyond COVID-19: a cross-sectional study in Italy exploring the covid collateral impacts on healthcare services. Health Policy. 2021;125(7):869–876.
   PubMed Web of Science ®Google Scholar
• Franchi C, Lucca U, Tettamanti M, et al. Cholinesterase inhibitor use in Alzheimer’s disease: the EPIFARM-elderly project. Pharmacoepidemiol Drug Saf. 2011;20(5):497–505.
   PubMed Web of Science ®Google Scholar
• Pariente A, Helmer C, Merliere Y, et al. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf. 2008;17(7):655–660.
   PubMed Web of Science ®Google Scholar
• Mattace-Raso F. Is memantine + acetylcholinesterase inhibitor treatment superior to either therapy alone in Alzheimer’s disease? JAD. 2014;41(2):641–642.
   Web of Science ®Google Scholar
• Chiatti C, Rimland JM, Bonfranceschi F, et al. Up-TECH research group. The up-TECH project, an intervention to support caregivers of Alzheimer’s disease patients in Italy: preliminary findings on recruitment and caregiving burden in the baseline population. Aging Ment Health. 2015;19(6):517–525.
   PubMed Web of Science ®Google Scholar
• Porcelli S, Calabrò M, Crisafulli C, et al. Alzheimer’s disease and neurotransmission gene variants: focus on their effects on psychiatric comorbidities and inflammatory parameters. Neuropsychobiology. 2019;78(2):79–85.
   PubMed Web of Science ®Google Scholar
• Sinforiani E, Bernini S, Picascia M, et al. Treatment adherence in patients with Alzheimer’s disease referred to an Italian center for dementia. Aging Clin Exp Res. 2015;27(3):395–396.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EMA/CHMP/158268/2017. Guideline on clinical development of fixed combination medicinal products. Available from www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-fixed-combination-medicinal-products-revision-2_en.pdf.
   Google Scholar
• Degli Esposti L, Perrone V, Veronesi C, et al. Modifications in drug adherence after switch to fixed-dose combination of perindopril/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlodipine-perindopril in real settings (AMPERES) study. Curr Med Res Opin. 2018;34(9):1571–1577.
   PubMed Web of Science ®Google Scholar
• Cho SJ, Oh IS, Jeong HE, et al. Long-term clinical outcomes of oral antidiabetic drugs as fixed‐dose combinations: a nationwide retrospective cohort study. Diabetes Obes Metab. 2022;24(10):2051–2060.
   PubMed Web of Science ®Google Scholar